A Phase 2/3 interventional study of Osivelotor in Sickle Cell Disease, sponsored by Pfizer. Terminated at 9 sites in 2 countries. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 15th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2023, is one of 2 in phase 2/3, and was the 29th registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:
Pfizer · Sites in United States, Brazil, India and 4 more countries
Ages 12+
By country, each count listing its studies:
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 6 Months and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 5 · Phase 3 11 · Phase 4 3
First in 2014; this study’s year is marked. 4 started in 2023.
This study's enrollment of 47 is above the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 52 across the 27 interventional studies, 216 across the 3 observational. Of the 28 that completed or were terminated, 19 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 32 studies in Anemia, Sickle Cell by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
An Open-label Extension Study of GBT021601 in Participants with Sickle Cell Disease
An Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of GBT021601 Administered to Participants with Sickle Cell Disease Who Have Participated in a GBT021601 Clinical Trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female aged 6 months or older with SCD who participated and received study drug or placebo in a previous osivelotor clinical study and completed the end of treatment visit.
Note: Participants who discontinued study drug in the originating study due to an TEAE, but who remained on study, may be eligible for treatment in this study provided the TEAE does not pose a risk for treatment with osivelotor.
Females of are required to have a negative urine pregnancy test prior to dosing on Day 1.
Note: Females who become of childbearing potential during the study must be willing to have negative urine pregnancy tests to remain in the study.
If sexually active, females of childbearing potential must consistently use highly effective methods of consistently throughout the study and for at least 120 days after the last dose of study drug. If sexually active, male participants must use barrier methods of contraception until 84 days after the last dose of study drug. Male participants are eligible to participate if they agree to the following requirements during the study intervention period and for 84 days after the last dose of study intervention:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Osivelotor
Drug: Osivelotor
Osivelotor
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. Serious adverse events (SAEs) were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other medically significant events. TEAEs are events between first dose of study drug and up to 56 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of any AE to treatment was based on investigator decision. AEs included both SAEs and all non-serious AEs.
Time frame: From first dose of study drug up to 56 days after last dose of study drug (approximately up to 736 days)
Change From Baseline in Hematocrit at Week 12
Change from baseline in hematocrit at week 12 were reported in this outcome measure.
Time frame: Baseline, Week 12
Change From Baseline in Hematocrit at Week 48
Change from baseline in hematocrit at week 48 were reported in this outcome measure.
Time frame: Baseline, Week 48
Change From Baseline in Leukocytes at Week 12
Change from baseline in leukocytes at week 12 were reported in this outcome measure.
Time frame: Baseline, Week 12
Change From Baseline in Leukocytes Week 48
Change from baseline in leukocytes at week 48 were reported in this outcome measure.
Time frame: Baseline, Week 48
Change From Baseline in Supine Blood Pressure (SBP) at Week 12
Change from baseline in SBP at week 12 were reported in this outcome measure.
Time frame: Baseline, Week 12
Change From Baseline in SBP at Week 48
Change from baseline in SBP at week 48 were reported in this outcome measure.
Time frame: Baseline, Week 48
Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12
Change from baseline in DBP at week 12 were reported in this outcome measure.
Time frame: Baseline, Week 12
Change From Baseline in DBP at Week 48
Change from baseline in DBP at week 48 were reported in this outcome measure.
Time frame: Baseline, Week 48
Annualized Rate of Vaso-Occlusive Crisis (VOC)
A VOC was defined as an acute episode of pain that had no medically determined cause other than a vaso-occlusive event, and resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), and required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC was reported in this outcome measure.
Time frame: From the first dose of study drug up to last dose of study drug (approximately up to 680 days)
Number of Participants With Sickle Cell Disease (SCD) Related Serious Adverse Events (SAEs)
SCD is an inherited disorder caused by a point mutation in the beta globin gene which leads to formation of sickle hemoglobin (HbS). SAEs were defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other medically significant events. Participants with delayed start are those with a gap in dosing greater than 42 consecutive days from completing the originating study (C5351005 Date of First Dose - C5351004 End of Treatment Date + 1 greater than 42).
Time frame: From first dose of study drug up to 56 days after last dose of study drug (approximately up to 736 days)
Change From Baseline in Hemoglobin at Weeks 12, 24, 36, 48, and 60
Change from baseline in hemoglobin at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.
Time frame: Baseline, Weeks 12, 24, 36, 48, and 60
Change From Baseline in Reticulocytes at Weeks 12, 24, 36, 48, and 60
Change from baseline in reticulocytes at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.
Time frame: Baseline, Weeks 12, 24, 36, 48, and 60
Change From Baseline in Lactate Dehydrogenase (LDH) at Weeks 12, 24, 36, 48, and 60
Change from baseline in LDH at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.
Time frame: Baseline, Weeks 12, 24, 36, 48, and 60
Change From Baseline in Unconjugated Bilirubin at Weeks 12, 24, 36, 48, and 60
Change from baseline in unconjugated bilirubin at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.
Time frame: Baseline, Weeks 12, 24, 36, 48, and 60
| Milestone | Participants Without Delayed Start: Osivelotor 100 Milligram (mg) | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Started | 18 | 17 | 1 | 5 | 6 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 18 | 17 | 1 | 5 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 12 | 16 | 1 | 4 | 6 |
| Withdrew: Withdrawal by subject | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study treatment | 1 | 0 | 0 | 0 | 0 |
An adverse event (AE) was any untoward medical occurrence in a participant administered a pharmaceutical product during the course of a clinical investigation. Serious adverse events (SAEs) were defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other medically significant events. TEAEs are events between first dose of study drug and up to 56 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Relatedness of any AE to treatment was based on investigator decision. AEs included both SAEs and all non-serious AEs.
| Participants | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| TEAE | 14 | 13 | 1 | 5 | 6 |
| Treatment related TEAE | 4 | 0 | 0 | 0 | 0 |
| Treatment emergent SAEs | 5 | 4 | 1 | 2 | 2 |
| Treatment-Related Treatment-Emergent SAEs | 1 | 0 | 0 | 0 | 0 |
| Treatment Emergent Non-Serious AEs | 14 | 13 | 1 | 5 | 5 |
Change from baseline in hematocrit at week 12 were reported in this outcome measure.
| Percent | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematocrit at Week 12 | -0.3 ± 5.88 | -3.9 ± 7.53 | -1.9 ± NA | 7.0 ± 5.74 | 10.0 ± 2.37 |
Change from baseline in hematocrit at week 48 were reported in this outcome measure.
| Percent | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change From Baseline in Hematocrit at Week 48 | -2.4 ± 7.71 | -5.5 ± 8.61 | -9.9 ± NA | 4.5 ± 4.12 | 5.5 ± 5.00 |
Change from baseline in leukocytes at week 12 were reported in this outcome measure.
| 10^9 cells per liter (10^9 cells/L) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change From Baseline in Leukocytes at Week 12 | 1.7 ± 2.68 | 0.8 ± 1.87 | 0.9 ± NA | 0.3 ± 1.92 | -1.8 ± 2.28 |
Change from baseline in leukocytes at week 48 were reported in this outcome measure.
| 10^9 cells/L | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change From Baseline in Leukocytes Week 48 | 1.7 ± 3.35 | 2.8 ± 3.22 | 2.4 ± NA | 1.0 ± 1.82 | -0.4 ± 1.74 |
Change from baseline in SBP at week 12 were reported in this outcome measure.
| Millimeters of mercury (mmHg) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change From Baseline in Supine Blood Pressure (SBP) at Week 12 | -3.4 ± 7.83 | -2.5 ± 10.72 | -3.0 ± NA | 2.0 ± 4.42 | 2.0 ± 5.10 |
Change from baseline in SBP at week 48 were reported in this outcome measure.
| mmHg | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change From Baseline in SBP at Week 48 | -2.5 ± 12.34 | -2.3 ± 11.48 | 0.0 ± NA | -0.8 ± 11.50 | -0.4 ± 9.43 |
Change from baseline in DBP at week 12 were reported in this outcome measure.
| mmHg | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12 | -3.9 ± 7.91 | -0.8 ± 7.28 | -2.0 ± NA | 1.0 ± 5.96 | -1.7 ± 14.04 |
Change from baseline in DBP at week 48 were reported in this outcome measure.
| mmHg | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change From Baseline in DBP at Week 48 | -4.4 ± 8.99 | -0.4 ± 7.62 | 1.0 ± NA | 4.3 ± 13.55 | -1.5 ± 16.77 |
A VOC was defined as an acute episode of pain that had no medically determined cause other than a vaso-occlusive event, and resulted in a visit to a medical facility (hospitalization, emergency department, urgent care center, outpatient clinic, or infusion center), and required parenteral narcotic agents, parenteral nonsteroidal anti-inflammatory drugs (NSAIDs), or an increase in treatment with oral narcotics. Annualized rate of VOC was reported in this outcome measure.
| VOC events per year | All Participants: Osivelotor 100 mg | All Participants: Osivelotor 150 mg | All Participants: Osivelotor 100 mg + 150 mg | All Participants: Osivelotor 200 mg |
|---|---|---|---|---|
| Annualized Rate of Vaso-Occlusive Crisis (VOC) | 1.01 (0.50 to 2.04) | 1.11 (0.59 to 2.09) | 1.07 (0.67 to 1.70) | NA (NA to NA) |
SCD is an inherited disorder caused by a point mutation in the beta globin gene which leads to formation of sickle hemoglobin (HbS). SAEs were defined as any untoward medical occurrence that, at any dose, meets one or more of the criteria: death, life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly or birth defect and other medically significant events. Participants with delayed start are those with a gap in dosing greater than 42 consecutive days from completing the originating study (C5351005 Date of First Dose - C5351004 End of Treatment Date + 1 greater than 42).
| Participants | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Number of Participants With Sickle Cell Disease (SCD) Related Serious Adverse Events (SAEs) | 0 | 2 | 1 | 0 | 0 |
Change from baseline in hemoglobin at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.
| Grams per deciliter (g/dL) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change at week 12 | 0.2 ± 1.68 | -0.6 ± 1.36 | -0.1 ± NA | 2.0 ± 1.55 | 3.4 ± 0.88 |
| Change at week 24 | 0.0 ± 1.64 | -0.9 ± 1.84 | 0.0 ± NA | 2.0 ± 1.70 | 2.4 ± 1.97 |
| Change at week 36 | -0.3 ± 1.49 | -1.2 ± 2.46 | 1.0 ± NA | 2.3 ± 1.35 | 2.1 ± 2.69 |
| Change at week 48 | -0.8 ± 2.65 | -1.4 ± 1.97 | -3.2 ± NA | 1.1 ± 1.10 | 1.6 ± 1.87 |
| Change at week 60 | -1.7 ± 1.67 | -2.5 ± 1.93 | — | 0.4 ± NA | 0.3 ± 0.71 |
Change from baseline in reticulocytes at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.
| 10^9 cells/L | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change at week 12 | 16.4 ± 106.94 | -1.2 ± 95.34 | 68.4 ± NA | 10.5 ± 90.08 | -24.7 ± 149.35 |
| Change at week 24 | -22.5 ± 132.67 | 26.7 ± 102.47 | -11.3 ± NA | -77.1 ± 75.00 | -52.9 ± 52.41 |
| Change at week 36 | 39.6 ± 99.22 | 82.9 ± 115.86 | -64.0 ± NA | 93.0 ± 161.13 | 25.7 ± 96.34 |
| Change at week 48 | 8.2 ± 105.75 | 34.4 ± 71.33 | 326.0 ± NA | 8.9 ± 138.88 | -45.4 ± 87.01 |
| Change at week 60 | -9.8 ± 136.44 | -8.1 ± 109.27 | — | -41.4 ± NA | -21.4 ± 175.33 |
Change from baseline in LDH at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.
| International units per liter (IU/L) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change at week 12 | -40.1 ± 176.92 | -20.0 ± 104.40 | 171.0 ± NA | 168.8 ± 703.08 | 107.8 ± 471.09 |
| Change at week 24 | 35.7 ± 103.08 | 9.9 ± 133.71 | 71.0 ± NA | -96.8 ± 144.55 | -78.5 ± 177.58 |
| Change at week 36 | 54.1 ± 80.90 | 22.6 ± 127.73 | 30.0 ± NA | -40.0 ± 177.92 | -67.7 ± 148.38 |
| Change at week 48 | 172.4 ± 358.05 | 78.0 ± 199.23 | 525.0 ± NA | -94.8 ± 124.77 | -18.4 ± 99.78 |
| Change at week 60 | 207.2 ± 298.85 | 70.4 ± 164.24 | — | -41.0 ± NA | 43.0 ± 72.12 |
Change from baseline in unconjugated bilirubin at weeks 12, 24, 36, 48 and 60 were reported in this outcome measure.
| Micromoles per liter (mcmol/L) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| Change at week 12 | 0.6 ± 6.88 | 0.3 ± 9.52 | — | -21.9 ± 16.21 | -3.8 ± 37.57 |
| Change at week 24 | -2.8 ± 4.55 | -4.9 ± 13.66 | — | -19.3 ± 20.20 | -3.4 ± 12.10 |
| Change at week 36 | -2.8 ± 19.47 | 1.6 ± 10.35 | — | -14.9 ± 32.98 | 2.1 ± 23.87 |
| Change at week 48 | 7.1 ± 31.00 | 8.5 ± 11.12 | — | -19.5 ± NA | -12.2 ± 21.88 |
| Change at week 60 | 0.5 ± 8.63 | 8.2 ± 21.07 | — | -0.5 ± NA | -13.0 ± NA |
Collected over From first dose of study drug up to 56 days after last dose of study drug (approximately up to 736 days). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants Without Delayed Start: Osivelotor 100 mg | 0/18 (0%) | 5/18 (27.8%) | 14/18 (77.8%) |
| Participants Without Delayed Start: Osivelotor 150 mg | 0/17 (0%) | 4/17 (23.5%) | 13/17 (76.5%) |
| Participants Without Delayed Start: Osivelotor 200 mg | 0/1 (0%) | 1/1 (100%) | 1/1 (100%) |
| Participants With Delayed Start: Osivelotor 100 mg | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Participants With Delayed Start: Osivelotor 150 mg | 0/6 (0%) | 2/6 (33.3%) | 5/6 (83.3%) |
| Event | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 0/18 | 1/17 | 1/1 | 0/5 | 0/6 |
| AnaemiaBlood and lymphatic system disorders | 1/18 | 1/17 | 0/1 | 1/5 | 1/6 |
| HaemolysisBlood and lymphatic system disorders | 1/18 | 0/17 | 0/1 | 1/5 | 0/6 |
| SepsisInfections and infestations | 0/18 | 0/17 | 0/1 | 1/5 | 1/6 |
| Thermal burnInjury, poisoning and procedural complications | 0/18 | 0/17 | 0/1 | 0/5 | 1/6 |
| CholecystitisHepatobiliary disorders | 0/18 | 1/17 | 0/1 | 0/5 | 0/6 |
| Vestibular neuronitisInfections and infestations | 0/18 | 1/17 | 0/1 | 0/5 | 0/6 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 0/18 | 1/17 | 0/1 | 0/5 | 0/6 |
| Tachycardia paroxysmalCardiac disorders | 1/18 | 0/17 | 0/1 | 0/5 | 0/6 |
| GastroenteritisInfections and infestations | 1/18 | 0/17 | 0/1 | 0/5 | 0/6 |
| Event | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/18 | 0/17 | 1/1 | 0/5 | 0/6 |
| Chest painGeneral disorders | 0/18 | 0/17 | 1/1 | 0/5 | 0/6 |
| PyrexiaGeneral disorders | 0/18 | 0/17 | 1/1 | 0/5 | 0/6 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/18 | 0/17 | 1/1 | 1/5 | 0/6 |
| Back painMusculoskeletal and connective tissue disorders | 0/18 | 1/17 | 1/1 | 0/5 | 0/6 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/18 | 0/17 | 1/1 | 0/5 | 0/6 |
| MalariaInfections and infestations | 4/18 | 7/17 | 0/1 | 3/5 | 3/6 |
| Urinary tract infectionInfections and infestations | 2/18 | 5/17 | 0/1 | 3/5 | 3/6 |
| PainGeneral disorders | 2/18 | 3/17 | 0/1 | 0/5 | 3/6 |
| MicroalbuminuriaRenal and urinary disorders | 0/18 | 0/17 | 0/1 | 2/5 | 0/6 |
Safety analysis set included all enrolled participants who had received at least one dose of study drug in this open-label extension (OLE) study. Participants were analyzed according to the assigned daily maintenance dose on study day 1 in the OLE study.
| Age, Continuous(Years) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg | Total |
|---|---|---|---|---|---|---|
| Mean | 33.4 ± 13.75 | 27.2 ± 10.19 | 27.0 ± NA | 26.4 ± 11.70 | 27.8 ± 14.41 | 29.6 ± 12.25 |
| Sex: Female, Male(Participants) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg | Total |
|---|---|---|---|---|---|---|
| Female | 9 | 11 | 1 | 3 | 4 | 28 |
| Male | 9 | 6 | 0 | 2 | 2 | 19 |
| Ethnicity (NIH/OMB)(Participants) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 18 | 17 | 1 | 5 | 6 | 47 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Participants Without Delayed Start: Osivelotor 100 mg | Participants Without Delayed Start: Osivelotor 150 mg | Participants Without Delayed Start: Osivelotor 200 mg | Participants With Delayed Start: Osivelotor 100 mg | Participants With Delayed Start: Osivelotor 150 mg | Total |
|---|---|---|---|---|---|---|
| Race — African | 10 | 12 | 0 | 5 | 6 | 33 |
| Race — Black or African American | 8 | 5 | 1 | 0 | 0 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jan 2023 to primary completion in Feb 2025, 25 months.
Results were first posted in Mar 2026, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osivelotor